What question did this study set out to answer?

To quantitatively analyze the efficacy and safety of centanafadine in treating ADHD through systematic review of RCTs.

June 12, 2026Open Access

Efficacy and Safety of Centanafadine in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

MMMuneeb Ahmad MuneerAllama Iqbal Medical College MNMashal NaveedAllama Iqbal Medical College MAMinahil AmjadAllama Iqbal Medical College

Key Points

To quantitatively analyze the efficacy and safety of centanafadine in treating ADHD through systematic review of RCTs.
Systematic review of RCTs evaluating centanafadine's efficacy and safety against placebo in ADHD patients.
Literature search across PubMed, Embase, Scopus, and ClinicalTrials.gov for relevant studies.
Data pooled as standardized mean differences using random-effects meta-analyses.
Centanafadine showed statistically significant improvement in ADHD symptoms with a standardized mean difference of Hedges' g (exact value not provided).
Safety analyses of six RCTs involving 2,287 participants indicated a risk ratio of 1.29 for adverse events (95% CI 0.97 to 1.71), which was not statistically significant.

Abstract

Background: Attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder associated with persistent functional impairment across the lifespan. Although several pharmacological treatments are available, their clinical utility is often limited by tolerability concerns, heterogeneous efficacy, and limited long-term safety data. Centanafadine, a novel triple monoamine reuptake inhibitor targeting norepinephrine, dopamine, and serotonin transporters, has emerged as a potential non-stimulant treatment for ADHD; however, its efficacy and safety have not been systematically quantified. Objective: To systematically review and quantitatively synthesize randomized controlled trials (RCTs evaluating the efficacy and safety of centanafadine compared with placebo in individuals with ADHD. Methods: PubMed, Embase, Scopus, and ClinicalTrials.gov were searched from inception to the most recent available date. Placebo-controlled RCTs enrolling participants with a formal ADHD diagnosis were included. Primary efficacy outcomes were changes in ADHD symptom severity assessed using validated rating scales and pooled as standardized mean differences (Hedges' g). Secondary efficacy outcomes included clinician-rated global severity assessed using the Clinical Global Impressions-Severity (CGI-S) scale. Safety outcomes included the incidence of any adverse event. Random-effects meta-analyses using restricted maximum-likelihood estimation with Hartung-Knapp adjustment were performed. Risk of bias was assessed using the Cochrane Risk of Bias 2.0 tool. Results: = 0%). Safety analyses of six RCTs (n = 2,287) showed a numerically higher but non-significant risk of adverse events (risk ratio = 1.29, 95% CI 0.97 to 1.71). Conclusions: Centanafadine provides statistically significant and clinically meaningful improvement in ADHD symptoms with generally acceptable tolerability, supporting its role as a non-stimulant treatment option. Further long-term and comparative trials are warranted.

Ask AI

Helpful

Bookmark

View Full Paper